1. European Medicines Agency. EPAR - Bavencio. [Internet]. Available from: 〈https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio〉. [Accessed April 20 2023].
2. European Medicines Agency. EPAR - Imfinzi. [Internet]. Available from: 〈https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi〉. [Accessed April 20 2023].
3. European Medicines Agency. EPAR - Tecentriq. [Internet]. Available from: 〈https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq〉. [Accessed April 20 2023].
4. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome;Alsaab;Front Pharm.,2017
5. European Medicines Agency. Assessment report - Tecentriq. [Internet]. Available from: 〈https://www.ema.europa.eu/en/documents/assessment-report/tecentriq-epar-public-assessment-report_en.pdf〉. [Accessed July 25 2023].